A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified April 2014 by GlaxoSmithKline
Sponsor:
Collaborator:
PPD
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT02105987
First received: April 3, 2014
Last updated: April 10, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: April 2016
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)